Cat. No.: HY-B0421

Mycophenolic acid

(Synonyms: Mycophenolate)

14 Cited Publications

Customer Review

Based on 14 publication(s) in Google Scholar

Mycophenolic acid is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC₅₀ of 0.24 µM. Mycophenolic acid demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid is an immunosuppressive agent. Antiangiogenic and antitumor effects.

For research use only. We do not sell to patients.

Purity: 99.94%
CAS No.: 24280-93-1
Formula: C₁₇H₂₀O₆
Molecular Weight:320.34

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Mycophenolic acid Chemical Structure

CAS No.: 24280-93-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (14)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Microbial Metabolite

Human Endogenous Metabolite

All Endogenous Metabolite Isoforms :

All Antibiotic Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	1.21 μM Compound: MPA; 1	Cytotoxicity against human A549 cells assessed as growth inhibition measured by SRB assay Cytotoxicity against human A549 cells assessed as growth inhibition measured by SRB assay	[PMID: 34044119]
A549	IC₅₀	0.4 μM Compound: 1	In vitro antitumor activity against A549 human NSCLC lung carcinoma cells In vitro antitumor activity against A549 human NSCLC lung carcinoma cells	10.1016/0960-894X(95)00130-L
BHK-21	EC₅₀	0.04 μM Compound: Mycophenolic acid	Inhibition of West Nile virus VLP replicon in BHK21 cell line Inhibition of West Nile virus VLP replicon in BHK21 cell line	[PMID: 16539402]
BHK-21	EC₅₀	1.4 μM Compound: Mycophenolic acid	Inhibition of West Nile viral Rluc-Neo-Rep in BHK21 cell line Inhibition of West Nile viral Rluc-Neo-Rep in BHK21 cell line	[PMID: 16539402]
BHK-21	CC₅₀	>100 μM Compound: M 5255	Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 19482481]
BHK-21	EC₅₀	>100 μM Compound: M 5255	Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	[PMID: 19482481]
BHK-21	EC₅₀	>100 μM Compound: M 5255	Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	[PMID: 19482481]
BHK-21	CC₅₀	>100 μM Compound: M 5255	Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	>100 μM Compound: M 5255	Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	>100 μM Compound: M 5255	Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	>100 μM Compound: M5255	Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
BHK-21	EC₅₀	>100 μM Compound: M5255	Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
BHK-21	CC₅₀	3.55 μM Compound: 61	cytotoxicity against golden hamster BHK-21 cells incubated for 72 hrs by MTT assay cytotoxicity against golden hamster BHK-21 cells incubated for 72 hrs by MTT assay	[PMID: 32845145]
CCRF-CEM	IC₅₀	0.34 μM Compound: MPA	In vitro secondary T-cell (CEM) proliferation assay In vitro secondary T-cell (CEM) proliferation assay	[PMID: 12014950]
CCRF-CEM	IC₅₀	0.39 μM Compound: MPA	Inhibitory activity against human T-lymphoblast CEM cell line using T cell proliferation assay Inhibitory activity against human T-lymphoblast CEM cell line using T cell proliferation assay	[PMID: 12127522]
CCRF-CEM	IC₅₀	0.39 μM Compound: MPA	The human T-lymphoblastCEM cell (ATCC) proliferation inhibitory activity was determined The human T-lymphoblastCEM cell (ATCC) proliferation inhibitory activity was determined	[PMID: 12270168]
CCRF-CEM	IC₅₀	0.39 μM Compound: MPA	Inhibitory concentration against human T-lymphoblast CEM cell line (ATCC) by CEM proliferation assay. Inhibitory concentration against human T-lymphoblast CEM cell line (ATCC) by CEM proliferation assay.	[PMID: 12270177]
CCRF-CEM	IC₅₀	0.39 μM Compound: MPA	Inhibitory activity against CEM cell proliferation Inhibitory activity against CEM cell proliferation	[PMID: 12565968]
CCRF-CEM	IC₅₀	0.39 μM Compound: MPA	Inhibitory activity against proliferation of CEM cell line Inhibitory activity against proliferation of CEM cell line	[PMID: 12565969]
CCRF-CEM	IC₅₀	340 nM Compound: MPA	Inhibition of CEM (human leukemia) cell proliferation. Inhibition of CEM (human leukemia) cell proliferation.	[PMID: 14505670]
CCRF-CEM	IC₅₀	0.54 μM Compound: MPA	Inhibition of CEM cell proliferation Inhibition of CEM cell proliferation	[PMID: 17585753]
CCRF-CEM	IC₅₀	>156 μM Compound: 1, MPA	Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay	[PMID: 22621840]
CCRF-CEM	IC₅₀	0.9 μM Compound: 1	Cytotoxic activity against HIV uninfected T4 lymphocytes (CEM cell line) Cytotoxic activity against HIV uninfected T4 lymphocytes (CEM cell line)	10.1016/0960-894X(95)00130-L
DU-145	IC₅₀	2.94 μM Compound: MPA	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30223117]
FaDu	IC₅₀	6.72 μM Compound: MPA; 1	Cytotoxicity against human FaDu cells assessed as growth inhibition measured by SRB assay Cytotoxicity against human FaDu cells assessed as growth inhibition measured by SRB assay	[PMID: 34044119]
Hepatocyte	EC₅₀	5.9 μM Compound: 1; MPA	Toxicity in human hepatocytes assessed by dehydrogenase activity measured after 48 hrs by CCK-8 assay Toxicity in human hepatocytes assessed by dehydrogenase activity measured after 48 hrs by CCK-8 assay	[PMID: 34055230]
HepG2	IC₅₀	>100 μM Compound: 92125597	HARVARD: Cytotoxicity in HepG2 cell line HARVARD: Cytotoxicity in HepG2 cell line	[PMID: 22586124]
HepG2	IC₅₀	1 μM Compound: 92125597	HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells	[PMID: 22586124]
HL-60	IC₅₀	9.76 μM Compound: 1, MPA	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 22621840]
HT-29	IC₅₀	6.48 μM Compound: MPA; 1	Cytotoxicity against human HT-29 cells assessed as growth inhibition measured by SRB assay Cytotoxicity against human HT-29 cells assessed as growth inhibition measured by SRB assay	[PMID: 34044119]
HT-29	IC₅₀	0.4 μM Compound: Mycophenolic acid	Inhibitory activity of compound against HT-29 human colon adenocarcinoma cell line Inhibitory activity of compound against HT-29 human colon adenocarcinoma cell line	[PMID: 8568826]
HT-29	IC₅₀	0.9 μM Compound: 1	In vitro antitumor activity against HT-29 human colon adenocarcinoma cells In vitro antitumor activity against HT-29 human colon adenocarcinoma cells	10.1016/0960-894X(95)00130-L
Huh-7	CC₅₀	>100 μM Compound: 1, MPA	Cytotoxicity against human Huh7.5 cells after 96 hrs by MTT assay Cytotoxicity against human Huh7.5 cells after 96 hrs by MTT assay	[PMID: 23999140]
Huh-7	IC₅₀	4.16 μM Compound: 1, MPA	Antiviral activity against HCV expressing pFL-J6/JFH/JC1 infected in human Huh7.5 cells assessed as inhibition of viral RNA synthesis after 96 hrs by one-step RT-PCR analysis Antiviral activity against HCV expressing pFL-J6/JFH/JC1 infected in human Huh7.5 cells assessed as inhibition of viral RNA synthesis after 96 hrs by one-step RT-PCR analysis	[PMID: 23999140]
HUVEC	IC₅₀	99.2 nM Compound: MPA	Antiproliferative activity against HUVEC as measured by [3H]thymidine incorporation Antiproliferative activity against HUVEC as measured by [3H]thymidine incorporation	[PMID: 16640327]
Jurkat	IC₅₀	128 nM Compound: MPA	Antiproliferative activity against Jurkat T cells as measured by [3H]thymidine incorporation Antiproliferative activity against Jurkat T cells as measured by [3H]thymidine incorporation	[PMID: 16640327]
Jurkat	IC₅₀	0.193 μM Compound: 1, MPA	Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 22621840]
Jurkat	EC₅₀	9.45 μM Compound: 1, MPA, Mycophenolic acid	Antiproliferative activity against human Jurkat cells assessed as incorporation of [3H]thymidine after 18 hrs by scintillation counting analysis Antiproliferative activity against human Jurkat cells assessed as incorporation of [3H]thymidine after 18 hrs by scintillation counting analysis	[PMID: 24121309]
Jurkat	IC₅₀	28.21 μM Compound: 1, MPA, Mycophenolic acid	Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 24121309]
Jurkat	EC₅₀	0.3 μM Compound: 1; MPA	Immunosuppression-mediated antiproliferative activity against human Jurkat T cells assessed as inhibition of cell growth incubated for 48 hrs by VPD450 staining based flow cytometry Immunosuppression-mediated antiproliferative activity against human Jurkat T cells assessed as inhibition of cell growth incubated for 48 hrs by VPD450 staining based flow cytometry	[PMID: 32007665]
Jurkat	IC₅₀	60.6 μM Compound: 1; MPA	Immunosuppression-mediated cytotoxicity against human Jurkat T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Immunosuppression-mediated cytotoxicity against human Jurkat T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32007665]
K562	IC₅₀	7.7 μM Compound: MPA	Antiproliferative activity against human K562 cells after 72 hrs Antiproliferative activity against human K562 cells after 72 hrs	[PMID: 17958343]
K562	IC₅₀	7.7 μM Compound: MPA, mycophenolic acid	Antiproliferative activity against human K562 cells after 72 hrs by MTS assay Antiproliferative activity against human K562 cells after 72 hrs by MTS assay	[PMID: 18038969]
K562	IC₅₀	7.7 μM Compound: MPA	Antiproliferative activity against human K562 cells after 72 hrs by MTS assay Antiproliferative activity against human K562 cells after 72 hrs by MTS assay	[PMID: 18809333]
K562	IC₅₀	0.19 μM Compound: 1, MPA	Cytotoxicity against human K562 cells after 72 hrs by trypan blue exclusion assay Cytotoxicity against human K562 cells after 72 hrs by trypan blue exclusion assay	[PMID: 20934342]
K562	IC₅₀	7.7 μM Compound: MPA	Antiproliferative activity against human K562 cells after 72 hrs by MTS assay Antiproliferative activity against human K562 cells after 72 hrs by MTS assay	[PMID: 21324702]
K562	IC₅₀	0.08 μM Compound: Mycophenolic acid (MPA)	Inhibitory activity against growth of human erythroleukemia K652 cells Inhibitory activity against growth of human erythroleukemia K652 cells	[PMID: 9484510]
L1210	IC₅₀	2.18 μM Compound: 1, MPA	Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay	[PMID: 22621840]
L1210	IC₅₀	<0.2 μM Compound: Mycophenolic acid	Inhibitory activity of compound against L1210 leukemia cells in tissue culture Inhibitory activity of compound against L1210 leukemia cells in tissue culture	[PMID: 8568826]
L1210	IC₅₀	<0.2 μM Compound: 1	In vitro antitumor activity against L1210 murine lymphocytic leukemia cells In vitro antitumor activity against L1210 murine lymphocytic leukemia cells	10.1016/0960-894X(95)00130-L
LLC-MK2	CC₅₀	3.44 μM Compound: 61	Cytotoxicity against Rhesus macaque LLC-MK2 cells incubated for 72 hrs by MTT assay Cytotoxicity against Rhesus macaque LLC-MK2 cells incubated for 72 hrs by MTT assay	[PMID: 32845145]
MCF7	IC₅₀	0.5 μM Compound: 1	In vitro antitumor activity against MCF-7 human breast adenocarcinoma cells In vitro antitumor activity against MCF-7 human breast adenocarcinoma cells	10.1016/0960-894X(95)00130-L
MDA-MB-231	IC₅₀	4.38 μM Compound: MPA	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30223117]
MDA-MB-231	IC₅₀	7.83 μM Compound: MPA; 1	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition measured by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition measured by SRB assay	[PMID: 34044119]
MIN6	EC₅₀	0.6 μM Compound: 1; MPA	Toxicity in mouse MIN6 cells assessed by dehydrogenase activity measured after 48 hrs by CCK-8 assay Toxicity in mouse MIN6 cells assessed by dehydrogenase activity measured after 48 hrs by CCK-8 assay	[PMID: 34055230]
MOLT-4	IC₅₀	0.075 μM Compound: 1, MPA	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	[PMID: 22621840]
MT4	CC₅₀	0.2 μM Compound: M 5255	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 19482481]
MT4	CC₅₀	0.2 μM Compound: M 5255	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 20359898]
MT4	CC₅₀	0.2 μM Compound: M 5255	Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay	[PMID: 25082514]
MT4	CC₅₀	0.2 μM Compound: M5255	Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 26443549]
PBMC	IC₅₀	0.13 μM Compound: MPA	Inhibition of T cell proliferation in PBMC cells Inhibition of T cell proliferation in PBMC cells	[PMID: 17585753]
PBMC	IC₅₀	1.28 μM Compound: 1, MPA	Antiproliferative activity against activated-human PBMC after 96 hrs by MTT assay Antiproliferative activity against activated-human PBMC after 96 hrs by MTT assay	[PMID: 22621840]
PBMC	IC₅₀	0.044 μM Compound: 1, MPA, Mycophenolic acid	Cytotoxicity against human PBMC after 72 hrs by MTT assay Cytotoxicity against human PBMC after 72 hrs by MTT assay	[PMID: 24121309]
PBMC	IC₅₀	>100 μM Compound: Mycophenolic acid	Cytotoxicity against human PBMC after 96 hrs by flow cytometry Cytotoxicity against human PBMC after 96 hrs by flow cytometry	[PMID: 24963543]
PBMC	IC₅₀	0.18 μM Compound: Mycophenolic acid	Immunosuppressive activity in anti-CD3/anti-CD28-induced human PBMC after 96 hrs by flow cytometry Immunosuppressive activity in anti-CD3/anti-CD28-induced human PBMC after 96 hrs by flow cytometry	[PMID: 24963543]
PBMC	EC₅₀	0.0301 μM Compound: 1; MPA	Immunosuppression-mediated antiproliferative activity against anti-CD3/anti-CD28-stimulated human PBMC cells assessed as inhibition of cell growth incubated for 72 hrs by VPD450 staining based flow cytometry Immunosuppression-mediated antiproliferative activity against anti-CD3/anti-CD28-stimulated human PBMC cells assessed as inhibition of cell growth incubated for 72 hrs by VPD450 staining based flow cytometry	[PMID: 32007665]
PBMC	IC₅₀	0.14 μM Compound: 1; MPA	Immunosuppression-mediated cytotoxicity against anti-CD3/anti-CD28-stimulated human PBMC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Immunosuppression-mediated cytotoxicity against anti-CD3/anti-CD28-stimulated human PBMC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32007665]
PSN1	IC₅₀	0.7 μM Compound: 1	In vitro antitumor activity against PSN-1 human pancreatic carcinoma cells In vitro antitumor activity against PSN-1 human pancreatic carcinoma cells	10.1016/0960-894X(95)00130-L
SH-SY5Y	IC₅₀	0.56 μM Compound: MPA; 1	Cytotoxicity against human SH-SY5Y cells assessed as growth inhibition measured by SRB assay Cytotoxicity against human SH-SY5Y cells assessed as growth inhibition measured by SRB assay	[PMID: 34044119]
T-cell	IC₅₀	0.28 μM Compound: MPA	Immunosuppressive activity in in mouse T-cells assessed as inhibition of concanavalin A-induced proliferation Immunosuppressive activity in in mouse T-cells assessed as inhibition of concanavalin A-induced proliferation	[PMID: 22172700]
T-cell	IC₅₀	0.32 μM Compound: 4, MPA	Immunosuppressive activity in C57BL/6 mouse T lymphocytes assessed as inhibition of cell proliferation after 72 hrs by MTT assay Immunosuppressive activity in C57BL/6 mouse T lymphocytes assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 22464133]
U-87MG ATCC	IC₅₀	10.69 μM Compound: MPA	Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30223117]
Vero	EC₅₀	0.04 μM Compound: Mycophenolic acid	Inhibition of Rluc-FL-WNV replicon in Vero cells Inhibition of Rluc-FL-WNV replicon in Vero cells	[PMID: 16539402]
Vero	EC₅₀	0.08 μM Compound: Mycophenolic acid	Inhibition of West Nile viral Rluc-Neo-Rep in Vero cells Inhibition of West Nile viral Rluc-Neo-Rep in Vero cells	[PMID: 16539402]
Vero	EC₅₀	5.7 μM Compound: MPA, Mycophenolic acid	Antiviral activity against Dengue virus 2 NGC infected in african green monkey Vero cells after 3 days by immunofluorescence assay Antiviral activity against Dengue virus 2 NGC infected in african green monkey Vero cells after 3 days by immunofluorescence assay	[PMID: 17360676]
Vero	CC₅₀	>=13 μM Compound: M 5255	Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining	[PMID: 19482481]
Vero	CC₅₀	>=13 μM Compound: M 5255	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 20359898]
Vero	EC₅₀	>13 μM Compound: M 5255	Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	>13 μM Compound: M 5255	Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	>13 μM Compound: M 5255	Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	0.6 μM Compound: M 5255	Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay	[PMID: 20359898]
Vero	CC₅₀	>=12.5 μM Compound: MA	Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining	[PMID: 22047799]
Vero	EC₅₀	1.5 μM Compound: MA	Antiviral activity against Vaccinia virus Lister Elstree infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 3 days using crystal violet staining Antiviral activity against Vaccinia virus Lister Elstree infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 3 days using crystal violet staining	[PMID: 22047799]
Vero	CC₅₀	>=12.5 μM Compound: Mycophenolic acid	Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay	[PMID: 22513121]
Vero	CC₅₀	624.34 μM Compound: 1, MPA	Cytotoxicity against african green monkey Vero cells after 96 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 96 hrs by MTT assay	[PMID: 23999140]
Vero	IC₅₀	10.15 μM Compound: 1, MPA	Antiviral activity against Coxsackie B3 virus Nancy in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs Antiviral activity against Coxsackie B3 virus Nancy in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs	[PMID: 23999140]
Vero	IC₅₀	69.36 μM Compound: 1, MPA	Antiviral activity against Coxsackie B6 virus Schmitt in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs Antiviral activity against Coxsackie B6 virus Schmitt in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs	[PMID: 23999140]
Vero	EC₅₀	>100 μM Compound: M 5255	Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	>100 μM Compound: M 5255	Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	>100 μM Compound: M 5255	Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	0.6 μM Compound: M 5255	Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	2 μM Compound: M 5255	Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	1.5 μM Compound: M5255	Antiviral activity against Vaccinia virus infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay Antiviral activity against Vaccinia virus infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay	[PMID: 25913116]
Vero	EC₅₀	1.5 μM Compound: Mycophenolic acid	Antiviral activity against Human Vaccinia virus ATCC VR-1549 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining Antiviral activity against Human Vaccinia virus ATCC VR-1549 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining	[PMID: 26119992]
Vero	EC₅₀	>250 μM Compound: MPA	Antiviral activity against Coxsackie virus B4 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Coxsackie virus B4 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	0.8 μM Compound: MPA	Antiviral activity against Para-influenza-3 virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Para-influenza-3 virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	1.8 μM Compound: MPA	Antiviral activity against Reovirus-1 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Reovirus-1 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	20 μM Compound: MPA	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	4 μM Compound: MPA	Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	4 μM Compound: MPA	Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	>100 μM Compound: Mycophenolic acid	Antiviral activity against Coxsackie B4 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Coxsackie B4 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	0.4 μM Compound: Mycophenolic acid	Antiviral activity against para influenza 3 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against para influenza 3 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	1.4 μM Compound: Mycophenolic acid	Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	1.8 μM Compound: Mycophenolic acid	Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	2.3 μM Compound: Mycophenolic acid	Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	20 μM Compound: Mycophenolic acid	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	CC₅₀	30 μM Compound: 138; MAP	Cytotoxicity against African green monkey Vero cells by neutral red dye uptake assay Cytotoxicity against African green monkey Vero cells by neutral red dye uptake assay	[PMID: 28689975]
Vero	CC₅₀	18.7 μM Compound: Mycophenolic acid	Cytotoxicity activity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay Cytotoxicity activity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay	[PMID: 32786878]
Vero	EC₅₀	1.8 μM Compound: M5255	Antiviral activity against Vaccinia virus infected African green monkey Vero 76 cells assessed as reduction in plaque number treated after viral infection measured after 3 days by plaque reduction assay Antiviral activity against Vaccinia virus infected African green monkey Vero 76 cells assessed as reduction in plaque number treated after viral infection measured after 3 days by plaque reduction assay	10.1007/s00044-012-0342-1
Vero 76	EC₅₀	>13 μM Compound: M 5255	Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	>13 μM Compound: M 5255	Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	0.6 μM Compound: M 5255	Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	1.5 μM Compound: Mycophenolic acid	Antiviral activity against Vaccinia virus Elstree-Lister ATCC VR-1549 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 3 days by crystal violet staining Antiviral activity against Vaccinia virus Elstree-Lister ATCC VR-1549 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 3 days by crystal violet staining	[PMID: 22513121]
Vero 76	CC₅₀	20 μM Compound: M 5255	Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay	[PMID: 25082514]
Vero 76	CC₅₀	19 μM Compound: M5255	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method	[PMID: 25913116]
Vero 76	CC₅₀	>100 μM Compound: Mycophenolic acid	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining	[PMID: 26119992]
Vero 76	CC₅₀	20 μM Compound: M5255	Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method	[PMID: 26443549]
Vero 76	EC₅₀	>100 μM Compound: M5255	Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	>100 μM Compound: M5255	Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	0.6 μM Compound: M5255	Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay	[PMID: 26443549]
Vero 76	CC₅₀	>12.5 μM Compound: MA	Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 27161176]
Vero 76	CC₅₀	9 μM Compound: M5255	Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay	[PMID: 29028528]
Vero 76	EC₅₀	1.8 μM Compound: M 5255	Antiviral activity against Vaccinia virus infected African green monkey Vero76 cells assessed as reduction of virus-induced plaque reduction after 3 days by MTT assay Antiviral activity against Vaccinia virus infected African green monkey Vero76 cells assessed as reduction of virus-induced plaque reduction after 3 days by MTT assay	10.1007/s00044-010-9513-0
VSMC	IC₅₀	1 μM Compound: MPA, mycophenolic acid	Antiproliferative activity against PDGF-induced rat aortic VSMC by colorimetric assay Antiproliferative activity against PDGF-induced rat aortic VSMC by colorimetric assay	[PMID: 18400498]

In Vitro

Mycophenolic acid demonstrates antiviral effects against a wide range of RNA viruses including influenza, dengue virus, Zika virus, rotavirus, CCHFV, and hantavirus^[1].
IMPDH is the rate-limiting enzyme in the de novo synthesis of guanosine nucleotides^[2].
Mycophenolic acid (0.01-1 μM; 72 hours) exhibits preferential antiproliferative activity against the endothelial cells and fibroblasts. Endothelial cells are most sensitive cells to Mycophenolic acid treatment with an IC₅₀ <500 nM for antimitotic effects^[2].
Fibroblasts are also prone to Mycophenolic acid-induced cell cycle inhibition but exhibit a higher IC₅₀ (<1 μM) compared with endothelial cells. The two human tumor cell lines A549 non-small cell lung cancer cells and PC3 prostate cancer cells show intermediate sensitivity with an IC₅₀ >1 μM. U87 glioblastoma cells are resistant against MPA treatment up to 1 μM^[2].
Mycophenolic acid (0.05-2 μM; 18 hours) exhibits a dose-dependent down-regulation of HDAC2 and MYC, whereas up-regulates NDRG1^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

Primary isolated human dermal microvascular endothelial cells (HDMVEC) , fibroblasts, U87 glioblastoma cells, PC3 prostate cancer cells, A549 non-small cell lung cancer cells
Concentration:

0.01, 0.1, 1 μM
Incubation Time:

72 hours
Result:

Exhibited preferential antiproliferative activity against HDMVEC and fibroblasts. Whereas U87 glioblastoma cells were resistant to treatment, A549 non-small cell lung cancer and PC3 prostate cancer cells showed intermediate sensitivity.

Western Blot Analysis^[2]

Cell Line:

HDMVEC
Concentration:

0, 0.05, 0.1, 0.5, 1, and 2 μM
Incubation Time:

18 hours
Result:

Showed a dose-dependent regulation of HDAC2, MYC, and NDRG1.

In Vivo

Mycophenolic acid exerts its antitumor effects via modulation of the tumor microenvironment, U87 tumor growth is markedly inhibited in vivo in BALB/c nude mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Athymic 8-week-old, 20 g BALB/c nu/nu mice bearing Mycophenolic acid-resistant human U87 tumor model^[2]
Dosage:

120 mg/kg MMF (the morpholinoethyl ester prodrug of Mycophenolic acid)
Administration:

Oral gavage; b.i.d.
Result:

MMF (the morpholinoethyl ester prodrug of Mycophenolic acid) significantly inhibited tumor growth (∼70% after day 14 after tumor implantation) in MMF-treated versus control mice.
Microvessel density (CD31 staining) and pericyte coverage determined by α-smooth muscle actin staining were markedly reduced in MMF-treated versus control tumors (44% and 78%, respectively).

Chemical Information

CAS No. 24280-93-1
Appearance Solid
Molecular Weight 320.34
Formula C₁₇H₂₀O₆
Color White to off-white
SMILES

O=C(O)CC/C(C)=C/CC1=C(O)C2=C(COC2=O)C(C)=C1OC
Synonyms

Mycophenolate
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
- Microorganisms
- Endogenous metabolite
several species of Penicillium
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (14)

All WBFlow CytometryCell Proliferation/Viability AssayIF

Sort by:

Journal Impact Factor

Nat Immunol

A method for predicting drugs that can boost the efficacy of immune checkpoint blockade. [Abstract]

2024 Apr;25(4):659-670. PMID: 38499799
Nat Commun

Nuclear IMPDH2 controls the DNA damage response by modulating PARP1 activity. [Abstract]

2024 Nov 12;15(1):9515. PMID: 39532854

Mycophenolic acid purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Nov 12;15(1):9515. [Abstract]

Mycophenolic acid (MPA) (0, 2.5, 7.5, 15 μM) treatment caused a dose-dependent increase of IMPDH2 protein levels.

Mycophenolic acid purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Nov 12;15(1):9515. [Abstract]

Mycophenolic acid (MPA) (0, 2.5, 7.5, 15 μM) treatment reduced viability at the highest concentration used (15 μM).

Mycophenolic acid purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Nov 12;15(1):9515. [Abstract]

HT-IF showed that there was a significant increase in ɣH2AX signal in Mycophenolic acid (MPA) treated cells already at 7.5 μM.
Sci Adv

12R-HETE acts as an endogenous ligand for Nur77 in the intestines and regulates NKp46+ ILC3 development. [Abstract]

2026 Feb 20;12(8):eadz8405. PMID: 41719391
J Transl Med

Wnt/β-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer. [Abstract]

2024 Feb 3;22(1):133. PMID: 38310229

Mycophenolic acid purchased from MedChemExpress. Usage Cited in: J Transl Med. 2024 Feb 3;22(1):133. [Abstract]

The apoptotic rate was analysed after Mycophenolic acid (MPA) and/or oxaliplatin treatment compared with that of untreated cells for 24 h by flow cytosmetry analysis in HCT8/L-OHP cells.
Sci Signal

Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer. [Abstract]

2024 Nov 26;17(864):eadp1375. PMID: 39591412
J Agric Food Chem

Mechanism of Intestinal Epithelial Absorption and Electrophysiological Regulation of the Shrimp Peptide QMDDQ. [Abstract]

2024 Jan 10;72(1):326-338. PMID: 38155399
ACS Omega

Infectious cDNA Clone of Chikungunya Virus 181/25 for Antiviral Assay Development. [Abstract]

2025 Dec 8;10(50):62145-62156. PMID: 41476561

Mycophenolic acid purchased from MedChemExpress. Usage Cited in: ACS Omega. 2025 Dec 8;10(50):62145-62156. [Abstract]

Dose response curves and % cell viability of mycophenolic acid (MPA) (10-100 μM) by MTT assay.
Bone

HIF-1α mediates osteoclast-induced disuse osteoporosis via cytoophidia in the femur of mice. [Abstract]

2023 Mar:168:116648. PMID: 36563716
Viruses

Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform. [Abstract]

2021 Jun 28;13(7):1255. PMID: 34203149
BMC Cancer

The integration of transcriptomics and metabolomics elucidates the antitumor mechanisms of mycophenolic acid in bladder cancer cells. [Abstract]

2025 Sep 30;25(1):1463. PMID: 41029501
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
J Viral Hepat

The Differential Effects of Immunosuppressants on Hepatitis E Virus Replication and the Triggered Inflammatory Responses in Macrophages. [Abstract]

2026 Jan;33(1):e70118. PMID: 41400072
SSRN

2025 Jul 9.
Curr Res Virol Sci

Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern. [Abstract]

2022;3:100019. PMID: 35072124

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (312.17 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.1217 mL

15.6084 mL

31.2168 mL

5 mM

0.6243 mL

3.1217 mL

6.2434 mL

10 mM

0.3122 mL

1.5608 mL

3.1217 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Corn Oil

Solubility: 33.33 mg/mL (104.05 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (537 KB)
- English - EN (537 KB)
- Français - FR (537 KB)
- Deutsch - DE (537 KB)
- Norwegian - NO (537 KB)
- Español - ES (537 KB)
- Swedish - SV (537 KB)
- Italian - IT (537 KB)
- Korean - KR (537 KB)
- Portuguese - PT (537 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Stephen R Welch, et al. Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform. Viruses. 2021 Jun 28;13(7):1255. [Content Brief]

[2]. Sophie Domhan, et al. Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther. 2008 Jun;7(6):1656-68. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.1217 mL	15.6084 mL	31.2168 mL	78.0421 mL
	5 mM	0.6243 mL	3.1217 mL	6.2434 mL	15.6084 mL
	10 mM	0.3122 mL	1.5608 mL	3.1217 mL	7.8042 mL
	15 mM	0.2081 mL	1.0406 mL	2.0811 mL	5.2028 mL
	20 mM	0.1561 mL	0.7804 mL	1.5608 mL	3.9021 mL
	25 mM	0.1249 mL	0.6243 mL	1.2487 mL	3.1217 mL
	30 mM	0.1041 mL	0.5203 mL	1.0406 mL	2.6014 mL
	40 mM	0.0780 mL	0.3902 mL	0.7804 mL	1.9511 mL
	50 mM	0.0624 mL	0.3122 mL	0.6243 mL	1.5608 mL
	60 mM	0.0520 mL	0.2601 mL	0.5203 mL	1.3007 mL
	80 mM	0.0390 mL	0.1951 mL	0.3902 mL	0.9755 mL
	100 mM	0.0312 mL	0.1561 mL	0.3122 mL	0.7804 mL

Mycophenolic acid

14 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Mycophenolic acid

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

Antifungal Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Microbial Metabolite Library

Rare Diseases Drug Library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Nephrotoxicity Compound Library

Fungal-Sourced Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Mycophenolic acid

All Endogenous Metabolite Isoforms

All Antibiotic Isoforms

Biological Activity

Chemical Information

Publications (14)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Mycophenolic acid Related Classifications

HY-B0421 Related Classifications